Immunologic aspects of lung diseases and cystic fibrosis

JAMA

Volumn 278, Issue 22, 1997, Pages 1924-1930

  Greenberger, Paul A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEOXYRIBONUCLEASE; DIETHYLCARBAMAZINE; HYDROXYUREA; IBUPROFEN; IMMUNOSUPPRESSIVE AGENT; PREDNISONE;

ALLERGIC PNEUMONITIS; ASBESTOSIS; CHURG STRAUSS SYNDROME; CYSTIC FIBROSIS; GOODPASTURE SYNDROME; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LOEFFLER PNEUMONIA; LUNG ASPERGILLOSIS; LUNG DISEASE; LUNG FIBROSIS; LUNG INFECTION; LUNG SARCOIDOSIS; OCCUPATIONAL LUNG DISEASE; PRIORITY JOURNAL; REVIEW;

EID: 0031457408     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.278.22.1924     Document Type: Review

References (58)

1. Greenberger PA, Miller TP, Roberts M, Smith LL. Allergic bronchopulmonary aspergillosis in patients with and without evidence of bronchiectasis. Ann Allergy. 1993;70:333-338.
2. Patterson R, Rosenberg M, Roberts M. Evidence that Aspergillus fumigatus growing in the airway of man can be a potent stimulus of specific and nonspecific IgE formation. Am J Med. 1977;63:257-262.
3. Greenberger PA, Smith LJ, Hsu CCS, Roberts M, Liotta JL. Analysis of bronchoalveolar lavage in allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol. 1988;82:164-170.
4. Brown JE, Greenberger PA, Yarnold PR. Soluble interleukin 2 receptors in patients with asthma and allergic bronchopulmonary aspergillosis. Ann Allergy Asthma Immunol. 1995;74:484-488.
5. Chauhan B, Knutsen AP, Hutcheson PS, Slavin RG, Bellone CJ. T cell subsets, epitope mapping, and HLA-restriction in patients with allergic bronchopulmonary aspergillosis. J Clin Invest. 1996;97: 2324-2331.
6. Greenberger PA. Allergic bronchopulmonary aspergillosis. In: Patterson R, Grammer LC, Greenberger PA, eds. Allergic Diseases. 5th ed. Philadelphia, Pa: Lippincott-Raven; 1997:555-577.
7. Denning DW, Van Wye JE, Lewiston NJ, Stevens DA. Adjunctive therapy of allergic bronchopulmonary aspergillosis with itraconazole. Chest. 1991;100:813-819.
8. Allen JN, Davis WB. Eosinophilic lung diseases. Am J Respir Crit Care Med. 1994;150:1423-1438.
9. Backman KS, Zull D, Patterson R. Diagnostic complexity in a patient with asthma, pulmonary infiltrates, and eosinophilia. Ann Allergy Asthma Immunol. 1995;75:391-400.
10. Matteson EL, Gold KN, Bloch DA, Hunder GG. Long-term survival of patients with Wegener's granulomatosis from the American College of Rheumatology Wegener's granulomatosis classification criteria cohort. Am J Med. 1996;101:129-134.
11. Bajema IM, Hagen EC, Van Der Woude FJ, Bruijn JA. Wegener's granulomatosis. J Lab Clin Med. 1997;129:17-22.
12. Boehme MWJ, Schmitt WH, Youinou P, Stremmel WR, Gross WL. Clinical relevance of elevated serum thrombomodulin and soluble E-selectin in patients with Wegener's granulomatosis and other systemic vasculitides. Am J Med. 1996;101:387-394.
13. Phills, JA, Harrold AJ, Whiteman GV, Perelmutter L. Pulmonary infiltrates, asthma, and eosinophilia due to Ascaris suum infestation in man. N Engl J Med. 1972;286:965-970.
14. van Haelst Pisani C, Kovach JS, Kita H, et al. Administration of interleukin-2 (IL-2) results in increased plasma concentrations of IL-5 and eosinophilia in patients with cancer. Blood. 1991;9:1538-1544.
15. Lindermann A, Ganser A, Herrmann F, et al. Biologic effects of recombinant human interleukin-3 in vivo. J Clin Oncol. 1991;9:2120-2127.
16. Gonzales-Chambers R, Rosenfeld C, Winkelstein A, Dameshek L. Eosinophilia resulting from administration of recombinant granulocyte-macrophage colony-stimulating factor (rh GM-CSF) in a patient with T-γ lymphoproliferative disease. Am J Hematol. 1991;36:157-159.
17. Goldiner PL, Carlon GC, Cvitkovic E, Schweizer O, Howland WS. Factors influencing postoperative morbidity and mortality in patients treated with bleomycin. BMJ. 1978;1:1664-1667.
18. Holoye PY, Luna MA, MacKay B, Bedrossian CWM. Bleomycin hypersensitivity pneumonitis. Ann Intern Med. 1978;88:47-49.
19. Cogan E, Schandene L, Crusiaux A, Cochaux P, Velu T, Goldman M. Clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome. N Engl J Med. 1994;330:535-538.
20. Prin L, Plumas J, Gruart V, et al. Elevated serum levels of soluble interleukin-2 receptor. Blood. 1991;78:2626-2632.
21. Webb JKG, Job CK, Gault EW. Tropical eosinophilia. Lancet. 1960;1:835-842.
22. Fink JN. Hypersensitivity pneumonitis. In: Patterson R, Grammer LC, Greenberger PA, eds. Allergic Diseases. 5th ed. Philadelphia, Pa: Lippincott-Raven; 1997:543-553.
23. Zissel G. Ernst M, Schlaak M, Muller-Quernheim J. Accessory function of alveolar macrophages from patients with sarcoidosis and other granulomatous and nongranulomatous lung diseases. J Invest Med. 1997;45:75-86.
24. Trentin L, Migone N, Zambello R, et al. Mechanisms accounting for lymphocytic alveolitis in hypersensitivity pneumonitis. J Immunol. 1990;145: 2147-2154.
25. Denis M, Ghadirian E. Transforming growth factor-β is generated in the course of hypersensitivity pneumonitis. Am J Respir Cell Mol Biol. 1992; 7:156-160.
26. Nakagawa-Yoshida K, Ando M, Etches, Dosman JA. Fatal cases of farmer's lung in a Canadian family. Chest. 1997;111:245-248.
27. Greenberger PA, Pien LC, Patterson R, Robinson P, Roberts M. End-stage lung and ultimately fatal disease in a bird-fancier. Am J Med. 1989;86: 119-122.
28. Malmberg P, Rask-Andersen A, Rosenhall L. Exposure to microorganisms associated with allergic alveolitis and febrile reactions to mold dust in farmers. Chest. 1993;103:1202-1209.
29. Hogan MB, Patterson R, Pore S, Corder WT, Wilson NW. Basement shower hypersensitivity pneumonitis secondary to Epicoccum nigrum. Chest. 1996;110:855-856.
30. Ando M, Arima K, Yoneda R, Tamura M. Japanese summer-type hypersensitivity pneumonitis: geographic distribution, home environment, and clinical characteristics of 621 cases. Am Rev Respir Dis. 1991;144:765-769.
31. Grammer LC, Patterson R. Trimellitic anhydride. In: Rom WN, ed. Environmental and Occupational Medicine. 3rd ed. New York, NY: Little Brown & Co. In press.
32. Mapel DW, Samet JM, Coultas DB. Corticosteroids and the treatment of idiopathic pulmonary fibrosis. Chest. 1996;110:1058-1067.
33. Silicosis and Silicate Disease Committee. Diseases associated with exposure to silica and nonfibrous silicate minerals. Arch Pathol Lab Med. 1988; 112:673-720.
34. Jagirdar J, Begin R, Dufresne A, Goswami S, Lee RC, Rom WN. Transforming growth factor-β (TGF-β) in silicosis. Am J Respir Crit Care Med. 1996;154:1076-1081.
35. Balmes J, Cullen MR, Matthay RA. Occupational and environmental lung disease. In: George RB, Light RW, Matthay MA, Matthay RA, eds. Chest Medicine. 2nd ed. Baltimore, Md: Williams & Wilkins; 1990:277-306.
36. Wilson CB. Goodpasture syndrome and other anti-basement membrane antibody diseases. In: Rich RR, Fleisher TA, Schwartz BD, Shearer WT, Strober W, eds. Clinical Immunology. St Louis, Mo: Mosby-Year Book; 1996:1185-1191.
37. Kalluri R, Sun MJ, Hudson BG, Neilson EG. The Goodpasture antigen. J Biol Chem. 1996;271:9062-9068.
38. Semenzato G, Zambello R, Trentin L, Agostini C. Cellular immunity in sarcoidosis and hypersensitivity pneumonitis. Chest. 1993;103(suppl):139S-143S.
39. Zissel G, Homolka J, Schlaak J, Schlaak M, Muller-Quernheim J. Anti-inflammatory cytokine release by alveolar macrophages in pulmonary sarcoidosis. Am J Respir Crit Care Med. 1996;154:713-719.
40. Hunninghake GW, Gilbert S, Pueringer R, et al. Outcome of the treatment for sarcoidosis. Am J Respir Crit Care Med. 1994;149:893-898.
41. Heatly T, Sekela M, Berger R. Single lungtransplantation involving a donor with documented pulmonary sarcoidosis. J Heart Lung Transplant. 1994; 13:720-723.
42. Weiner Miller P, Hamosh A, Macek JM Jr, et al. Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in allergic bronchopulmonary aspergillosis. Am J Hum Genet. 1996;59:45-51.
43. Davis PB, Drumm M, Konstan MW. Cystic fibrosis. Am J Resp Crit Care Med. 1996;154:1229-1256.
44. Steinbach S, Sun L, Jiang R-Z, et al. Transmissibility of Pseudomonas cepacia infection in clinic patients and lung-transplant recipients with cystic fibrosis. N Engl J Med. 1994;331:981-987.
45. Knowles MR, Clarke LL, Boucher RC. Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis. N Engl J Med. 1991;325:533-538.
46. 4 markedly elevated in the epithelial lining fluid of patients with cystic fibrosis. Am Rev Respir Dis. 1993;148:896-901.
47. Davis PB. Cystic fibrosis from bench to bedside. N Engl J Med. 1991;325:575-576.
48. Birrer P, McElvaney NG, Rudeberg A, et al. Protease-antiprotease imbalance in the lungs of children with cystic fibrosis. Am J Respir Crit Care Med. 1994;150:207-213.
49. Becker JW, Burke W, McDonald G, Greenberger PA, Henderson WR, Aitken ML. Prevalence of allergic bronchopulmonary aspergillosis in adult patients with cystic fibrosis. Chest. 1996;109:1536-1540.
50. Laufer P, Fink J, Bruns W, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis. J Allergy Clin Immunol. 1984;73:44-48.
51. Nikolaizik WH, Moser M, Crameri R, et al. Identification of allergic bronchopulmonary aspergillosis in cystic fibrosis patients by recombinant Aspergillus fumigatus I/a-specific serology. Am J Resp Crit Care Med. 1995;152:634-639.
52. Cystic Fibrosis Foundation Center Committee and Guidelines Subcommittee. Cystic Fibrosis Foundation guidelines for patient services, evaluation, and monitoring in cystic fibrosis centers. AJDC. 1990;144:1311-1312.
53. Auerbach HS, Williams M, Kirkpatrick JA, Colten HR. Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet. 1985;2:686-688.
54. Konstan MW, Byard PJ, Hoppel CL, Davis PB. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med. 1995;332:848-854.
55. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med. 1994;331:637-642.
56. Knowles MR, Church NL, Waltner WE, et al. A pilot study of aerosolized amiloride for the treatment of lung disease of cystic fibrosis. N Engl J Med. 1990;322:1189-1194.
57. Regelmann WE, Elliott GR, Warwick WJ, Clawson CC. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am Rev Respir Dis. 1990;141:914-921.
58. Smith JJ, Travis SM, Greenberg EP, Welsh MJ. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell. 1996; 85:229-236.